News

Seven members of the pulmonary hypertension (PH) community — ranging from an 11-year-old advocate diagnosed in infancy to a physician who has led clinical trials, to a longtime fundraiser who’s a retired teacher — have been honored for their dedication and service by the Pulmonary Hypertension Association (PHA).

Pulmonary hypertension (PH) induced in response to exercise may be linked to a higher risk of cardiovascular (CV) disease in patients with human immunodeficiency virus (HIV), a small study found. Those with a higher CV risk had fewer CD4 T-cells, a type of immune cell that drops to extremely…

Treatment with an analog of sotatercept, Acceleron Pharma’s experimental therapy, eased disease-associated inflammation and changes in blood vessel architecture in multiple rodent models of pulmonary arterial hypertension (PAH), a study reported. The study, “Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension,” was published in…

A research form of Keros Therapeutics’ investigational therapy KER-012, called RKER-012, reduced lung inflammation and scarring (fibrosis) in a rat model of pulmonary arterial hypertension (PAH). The therapy also prevented an increase in the levels of a heart damage marker, the company announced in a press release. The…

Seralutinib (GB002), an investigational inhaled treatment for pulmonary arterial hypertension (PAH), effectively treated severe disease in two animal models, a study demonstrated. Further, when compared directly, inhaled seralutinib showed greater efficacy than imatinib, an approved cancer therapy also being investigated for PAH. Gossamer Bio, seralutinib’s developer, now is testing…

Treatment with cannabidiol (CBD) reduced inflammation and lessened damaging oxidative stress in a rat model of pulmonary hypertension (PH), a new study reports. “The promising results of our research may form the basis for a more detailed study of the effects of CBD or its derivatives on PH, especially…

Despite recent advances in care, mortality while in the intensive care unit (ICU) and up to one year thereafter remains high among people with pulmonary arterial hypertension (PAH), a new study reports. Risk factors for mortality one year after ICU discharge included low blood sodium, raised pro-B-type natriuretic peptide…

High scores on a measure known as H2FPEF — which reflect an increased probability of dysfunction of the left ventricle (LV) of the heart — were associated with signs of LV impairment and a worse prognosis in patients with idiopathic pulmonary arterial hypertension (IPAH), a study found. Patients with…

Sacubitril-valsartan — a combination oral therapy approved to treat heart failure — rapidly reduces pulmonary blood pressure in people with pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF), according to data from a Phase 3 clinical trial. Notably, these benefits were accompanied by reduced lung…

People with pulmonary hypertension (PH) who were diagnosed with COVID-19 had a high rate of hospitalization and in-hospital mortality, a French study concluded. Risk factors for adverse outcomes included being older, male, having co-existing conditions, or comorbidities, and having more severe PH. Anticoagulants (blood thinners) were the only treatment…

A mean pulmonary artery pressure (mPAP) — blood pressure in the lungs — of less than 40 mmHg (millimeters of mercury) significantly increases the survival rate of patients with different subsets of pulmonary arterial hypertension (PAH), a study suggests. The successful outcome was achieved with an intensive therapeutic approach…

Anumana’s electrocardiogram (ECG)-based algorithm for the early detection of pulmonary hypertension (PH) has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). Developed through a collaboration of scientists at Anumana, Janssen Research and Development, and the Mayo Clinic, the artificial intelligence (AI)-powered algorithm is designed…